CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the Rory David Deutsch Distinguished Professor of Neuro-Oncology and the Director of The Preston Robert Tisch Brain Tumor Center at Duke University. Amir F. Heshmatpour ...

CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is th ...

NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew" on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies, and Dr. Thomas Chen, CEO and Chief Medical Officer, will sit down with Dr. Drew—who earned his medical degree from the University of Southern California (USC)—to explain NeOnc’s platform technology. CALABASAS, Calif., S ...

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc’s drug discovery engine and helps accelerate its mission to develop therapies for c ...

The definitive agreement follows NeOnc's Board unanimously approving the company's participation in the contemplated $50 million equity investment and MENA region expansion, reflecting continued momentum. "We're thrilled to take this transformative step in formalizing our strategic partnership with Quazar," said Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies Holdings, Inc. "This definitive agreement sets the stage for accelerated global expansion and scientific innovation. As part of ...

Core Points - NeOnc Technologies Holdings, Inc. is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers [1][4] - The company will have its Executive Chairman, Amir Heshmatpour, featured in a live interview on July 24, 2025, at 11:00 a.m. ET [1] - NeOnc has executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment [2] - The company has been included in the Russell Microcap Index, which is part of its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is dedicated to developing and commercializing therapeutics that address challenges in overcoming the blood-brain barrier [4] - The company's NEO™ drug development platform has produced a portfolio of novel drug candidates with patent protections extending to 2038 [4] - NeOnc's NEO100™ and NEO212™ therapeutics are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [4]

Core Insights - NeOnc Technologies Holdings, Inc. is advancing transformative treatments for brain and central nervous system cancers and is featured in a live interview with financial commentator Kenny Polcari [1][4] - The company executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment, aimed at expanding its market presence in the UAE and broader GCC and MENA regions [2] - NeOnc was included in the Russell Microcap Index, which aligns with its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is a clinical-stage life sciences company focused on developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [4] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and IND status [4]

Core Insights - NeOnc Technologies Holdings, Inc. has received formal approval from its Board of Directors for a strategic transaction with Quazar Investment, marking a significant step towards closing the deal [1][2][3] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on developing treatments for brain and central nervous system cancers, utilizing its NEO™ drug development platform [5] - The company’s proprietary chemotherapy agents, including NEO100™ and NEO212™, are currently in Phase II clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [5] Strategic Partnership - The Board's unanimous approval allows NeOnc to participate in a $50 million equity investment and expansion into the MENA region under a non-binding term sheet with Quazar [2][3] - Quazar plans to lead a capital formation round priced at $25 per share, with 70% of proceeds allocated to acquiring NeOnc common stock and 30% for clinical trials and infrastructure development in the UAE and MENA region [3] Transaction Milestones - The transaction requires NeOnc to meet five milestones, with the current Board approval being the first of these [2][4] - NeOnc has 120 days to satisfy the remaining conditions necessary for closing the transaction [4] Future Developments - The strategic partnership aims to establish a strong operational presence in the MENA region and accelerate the clinical development of NeOnc's core assets [3] - Key future actions include the legal formation of NuroMENA and NuroCure in Abu Dhabi, execution of a Sub-License Agreement, finalization of offering documents, and approval of a comprehensive business plan [8]

Core Insights - NeOnc Technologies Holdings, Inc. has been included in the Russell Microcap® Index, which is a significant recognition of the company's growth and commitment to shareholder value [1][3] - The Russell Microcap® Index includes companies with an average market capitalization of approximately $640 million, covering stocks ranging from about $30 million to $3 billion [3][4] - NeOnc is focused on advancing its Phase II clinical trials for CNS cancers and expanding into the MENA region through a proposed partnership with Quazar [3] Company Overview - NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for central nervous system cancers and disorders [1][6] - The company utilizes the NEO™ drug development platform, which has produced a portfolio of novel drug candidates with patent protections extending to 2038 [6] - NeOnc's therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [6] Industry Context - The Russell US Indexes reconstitution ranks the 4,000 largest US stocks by total market capitalization, and membership in the Russell Microcap® Index is valid for one year [2][4] - Russell indexes are widely utilized by investment managers and institutional investors, serving as benchmarks for approximately $10.6 trillion in assets as of June 2024 [4]